Shay Capital’s Biogen BIIB Stock Holding History

Shay Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,000	Closed	-$1.26M	–	501
2025 Q3	$1.26M	Buy	+9,000	New	+$1.22M	0.11%	152
2023 Q4	–	Sell	-900	Closed	-$231K	–	296
2023 Q3	$231K	Buy	+900	New	+$241K	0.03%	238
2023 Q2	–	Sell	-1,756	Closed	-$488K	–	421
2023 Q1	$488K	Buy	+1,756	New	+$486K	0.1%	174
2022 Q4	–	Sell	-7,716	Closed	-$2.06M	–	294
2022 Q3	$2.06M	Buy	+7,716	New	+$1.64M	0.44%	39

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Shay Capital's BIIB Position: Q4 2025 in Review

Shay Capital sold out of Biogen (BIIB) in Q4 2025, closing a stake of 9,000 shares — an estimated $1.26M sold.

Shay Capital first reported a position in BIIB in Q3 2022 and held it in 4 quarters. The position peaked at $2.06M in Q3 2022. 1,000 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Shay Capital reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Shay Capital sold 9,000 Biogen shares in Q4 2025, an estimated $1.26M.
Shay Capital first reported a position in Biogen in Q3 2022 and held it in 4 quarters.
Shay Capital's Biogen position peaked at $2.06M in Q3 2022.
1,000 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Shay Capital's 13F filing for Q4 2025, filed 17 Feb 2026.